Lipoprotein (a) Screening, and What's Next?

1. Pearson K, Rodriguez F. Lipoprotein(a) and Cardiovascular Disease Prevention across Diverse Populations. Cardiol Ther. 2020;9:275–292. doi: 10.1007/s40119-020-00177-4 PearsonK RodriguezF Lipoprotein(a) and Cardiovascular Disease Prevention across Diverse Populations Cardiol Ther 2020 9 275 292 10.1007/s40119-020-00177-4 Open DOISearch in Google Scholar

2. Pasławska A, Tomasik PJ. Lipoprotein(a)-60 Years Later-What Do We Know? Cells. 2023;12(20):2472. doi: 10.3390/cells12202472 PasławskaA TomasikPJ Lipoprotein(a)-60 Years Later-What Do We Know? Cells 2023 12 20 2472 10.3390/cells12202472 Open DOISearch in Google Scholar

3. Jawi MM, Frohlich J, Chan SY. Lipoprotein(a) the Insurgent: A New Insight into the Structure, Function, Metabolism, Pathogenicity, and Medications Affecting Lipoprotein(a) Molecule. J Lipids. 2020;3491764. doi: 10.1155/2020/3491764 JawiMM FrohlichJ ChanSY Lipoprotein(a) the Insurgent: A New Insight into the Structure, Function, Metabolism, Pathogenicity, and Medications Affecting Lipoprotein(a) Molecule J Lipids 2020 3491764 10.1155/2020/3491764 Open DOISearch in Google Scholar

4. Iannuzzo G, Tripaldella M, Mallardo V, et al. Lipoprotein(a) Where Do We Stand? From the Physiopathology to Innovative Therapy. Biomedicines. 2021;9:838. doi: 10.3390/biomedicines9070838 IannuzzoG TripaldellaM MallardoV Lipoprotein(a) Where Do We Stand? From the Physiopathology to Innovative Therapy Biomedicines 2021 9 838 10.3390/biomedicines9070838 Open DOISearch in Google Scholar

5. Tada H, Takamura M, Kawashiri MA. Lipoprotein(a) as an Old and New Causal Risk Factor of Atherosclerotic Cardiovascular Disease. J Atheroscler Thromb. 2019;26:583–591. doi: 10.5551/jat.RV17034 TadaH TakamuraM KawashiriMA Lipoprotein(a) as an Old and New Causal Risk Factor of Atherosclerotic Cardiovascular Disease J Atheroscler Thromb 2019 26 583 591 10.5551/jat.RV17034 Open DOISearch in Google Scholar

6. Berman AN, Blankstein R. Current and future role of lipoprotein(a) in preventive cardiology. Curr Opin Cardiol. 2019;34:514–518. doi: 10.1097/HCO.0000000000000661 BermanAN BlanksteinR Current and future role of lipoprotein(a) in preventive cardiology Curr Opin Cardiol 2019 34 514 518 10.1097/HCO.0000000000000661 Open DOISearch in Google Scholar

7. Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). Eur Heart J. 2020;41:111–188. doi: 10.1093/eurheartj/ehz455 MachF BaigentC CatapanoAL 2019 ESC/EAS Guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) Eur Heart J 2020 41 111 188 10.1093/eurheartj/ehz455 Open DOISearch in Google Scholar

8. Cegla J, Neely RDG, France M, et al. HEART UK consensus statement on Lipoprotein(a): A call to action. Atherosclerosis. 2019;291:62–70. doi: 10.1016/j.atherosclerosis.2019.10.011 CeglaJ NeelyRDG FranceM HEART UK consensus statement on Lipoprotein(a): A call to action Atherosclerosis 2019 291 62 70 10.1016/j.atherosclerosis.2019.10.011 Open DOISearch in Google Scholar

9. Koschinsky ML, Kronenberg F. The long journey of lipoprotein(a) from cardiovascular curiosity to therapeutic target. Atherosclerosis. 2022;349:1–6. doi: 10.1016/j.atherosclerosis.2022.04.017 KoschinskyML KronenbergF The long journey of lipoprotein(a) from cardiovascular curiosity to therapeutic target Atherosclerosis 2022 349 1 6 10.1016/j.atherosclerosis.2022.04.017 Open DOISearch in Google Scholar

10. Shah NP, Pajidipati NJ, McGarrah RW, et al. Lipoprotein(a): An Update on a Marker of Residual Risk and Associated Clinical Manifestations. Am J Cardiol. 2020;126:94–102. doi: 10.1016/j.amjcard.2020.03.043 ShahNP PajidipatiNJ McGarrahRW Lipoprotein(a): An Update on a Marker of Residual Risk and Associated Clinical Manifestations Am J Cardiol 2020 126 94 102 10.1016/j.amjcard.2020.03.043 Open DOISearch in Google Scholar

11. Enkhmaa B, Petersen KS, Kris-Etherton PM, et al. Diet and Lp(a): Does dietary change modify residual cardiovascular risk conferred by Lp(a)? Nutrients. 2020;12:2024. doi: 10.3390/nu12072024 EnkhmaaB PetersenKS Kris-EthertonPM Diet and Lp(a): Does dietary change modify residual cardiovascular risk conferred by Lp(a)? Nutrients 2020 12 2024 10.3390/nu12072024 Open DOISearch in Google Scholar

12. Bhatia HS, Wilkinson MJ. Lipoprotein(a): Evidence for role as a Causal Risk Factor in cardiovascular Disease and Emerging Therapies. J Clin Med. 2022;11:6040. doi: 10.3390/jcm11206040 BhatiaHS WilkinsonMJ Lipoprotein(a): Evidence for role as a Causal Risk Factor in cardiovascular Disease and Emerging Therapies J Clin Med 2022 11 6040 10.3390/jcm11206040 Open DOISearch in Google Scholar

13. Kronenberg F. Lipoproteina(a). Handb Exp Pharmacol. 2022;270:201–232. doi: 10.1007/164_2021_504 KronenbergF Lipoproteina(a) Handb Exp Pharmacol 2022 270 201 232 10.1007/164_2021_504 Open DOISearch in Google Scholar

14. Kohn B, Ashraf AP, Wilson DP. Should Lipoprotein(a) be Measured in Youth? J Pediatr. 2021;228:285–289. doi: 10.1016/j.jpeds.2020.08.042 KohnB AshrafAP WilsonDP Should Lipoprotein(a) be Measured in Youth? J Pediatr 2021 228 285 289 10.1016/j.jpeds.2020.08.042 Open DOISearch in Google Scholar

15. Enkhmaa B, Berglund L. Non-genetic influences on lipoprotein(a) concentrations. Atherosclerosis. 2022;349:53–62. doi: 10.1016/j.atherosclerosis.2022.04.006 EnkhmaaB BerglundL Non-genetic influences on lipoprotein(a) concentrations Atherosclerosis 2022 349 53 62 10.1016/j.atherosclerosis.2022.04.006 Open DOISearch in Google Scholar

16. Hopewell JC, Haynes R, Baigent C. The role of lipoprotein(a) in chronic kidney disease. J Lipid Res. 2018;59:577–585. doi: 10.1194/jlr.R083626 HopewellJC HaynesR BaigentC The role of lipoprotein(a) in chronic kidney disease J Lipid Res 2018 59 577 585 10.1194/jlr.R083626 Open DOISearch in Google Scholar

17. Gitto S, Cicero AFG, Logg E, et al. Worsening of serum lipid profile after direct acting antiviral treatment. Ann Hepatol. 2018;17:64–75. doi: 10.5604/01.3001.0010.7536 GittoS CiceroAFG LoggE Worsening of serum lipid profile after direct acting antiviral treatment Ann Hepatol 2018 17 64 75 10.5604/01.3001.0010.7536 Open DOISearch in Google Scholar

18. Telyuk P, Austin D, Luvai A, et al. Lipoprotein(a): Insights for the Practicing Clinician. J Clin Med. 2022;11:3673. doi: 10.3390/jcm11133673 TelyukP AustinD LuvaiA Lipoprotein(a): Insights for the Practicing Clinician J Clin Med 2022 11 3673 10.3390/jcm11133673 Open DOISearch in Google Scholar

19. Kronenberg F. Lipoprotein(a) measurement issues: Are we making a mountain out of a Molehill? Atherosclerosis. 2022;349:123–135. doi: 10.1016/j.atherosclerosis.2022.04.008 KronenbergF Lipoprotein(a) measurement issues: Are we making a mountain out of a Molehill? Atherosclerosis 2022 349 123 135 10.1016/j.atherosclerosis.2022.04.008 Open DOISearch in Google Scholar

20. Banach M. Wytyczne PTL/KLRWP/PTK/PTDL/PTD/PTNT diagnostyki i leczenia zaburzeń lipidowych w Polsce. 2021. BanachM Wytyczne PTL/KLRWP/PTK/PTDL/PTD/PTNT diagnostyki i leczenia zaburzeń lipidowych w Polsce 2021 Search in Google Scholar

21. Solnica B, Sygitowicz G, Sitkiewicz D, et al. 2020 Guidelines of the Polish Society of Laboratory Diagnostics (PSLD) and the Polish Lipid Association (PoLA) on laboratory diagnostics of lipid metabolism disorders. Arch Med Sci. 2020;16(2):237–252. doi: 10.5114/aoms.2020.93253 SolnicaB SygitowiczG SitkiewiczD 2020 Guidelines of the Polish Society of Laboratory Diagnostics (PSLD) and the Polish Lipid Association (PoLA) on laboratory diagnostics of lipid metabolism disorders Arch Med Sci 2020 16 2 237 252 10.5114/aoms.2020.93253 Open DOISearch in Google Scholar

22. Wilson DP, Jacobson TA, Jones PH, et al. Use of Lipoprotein(a) in clinical practice: A biomarker whose time has come. A scientific statement from the National Lipid Association. J Clin Lipidol. 2019;13:374–392. doi: 10.1016/j.jacl.2019.04.010 WilsonDP JacobsonTA JonesPH Use of Lipoprotein(a) in clinical practice: A biomarker whose time has come. A scientific statement from the National Lipid Association J Clin Lipidol 2019 13 374 392 10.1016/j.jacl.2019.04.010 Open DOISearch in Google Scholar

23. Stone NJ, Smith SC, Orringer CE, et al. Managing Atherosclerotic Cardiovascular Risk in Young Adults: JACC State-of-the-Art Review. J Am Coll Cardiol. 2022;79:819–836. doi: 10.1016/j.jacc.2021.12.016 StoneNJ SmithSC OrringerCE Managing Atherosclerotic Cardiovascular Risk in Young Adults: JACC State-of-the-Art Review J Am Coll Cardiol 2022 79 819 836 10.1016/j.jacc.2021.12.016 Open DOISearch in Google Scholar

24. Patel AP, Wang M, Pirruccello JP, et al. Lp(a) (Lipoprotein[a]) concentrations and incident atherosclerotic cardiovascular disease: New insights from a large National Biobank. Arterioscler Thromb Vasc Biol. 2021;41:465–474. doi: 10.1161/ATVBAHA.120.315291 PatelAP WangM PirruccelloJP Lp(a) (Lipoprotein[a]) concentrations and incident atherosclerotic cardiovascular disease: New insights from a large National Biobank Arterioscler Thromb Vasc Biol 2021 41 465 474 10.1161/ATVBAHA.120.315291 Open DOISearch in Google Scholar

25. Mohammadi-Shemirani P, Chong M, Narula S, et al. Elevated Lipoprotein(a) and Risk of Atrial Fibrillation: An Observational and Mendelian Randomization Study. J Am Coll Cardiol. 2022;79:1579–1590. doi: 10.1016/j.jacc.2022.02.018 Mohammadi-ShemiraniP ChongM NarulaS Elevated Lipoprotein(a) and Risk of Atrial Fibrillation: An Observational and Mendelian Randomization Study J Am Coll Cardiol 2022 79 1579 1590 10.1016/j.jacc.2022.02.018 Open DOISearch in Google Scholar

26. Langsted A, Nordestgaard BG, Kamstrup PR. Elevated Lipoprotein(a) and Risk of Ischemic Stroke. J Am Coll Cardiol. 2019;74:54–66. doi: 10.1016/j.jacc.2019.03.524 LangstedA NordestgaardBG KamstrupPR Elevated Lipoprotein(a) and Risk of Ischemic Stroke J Am Coll Cardiol 2019 74 54 66 10.1016/j.jacc.2019.03.524 Open DOISearch in Google Scholar

27. Larsson SC, Gill D, Mason AM, et al. Lipoprotein(a) in Alzheimer, Atherosclerotic, Cerebrovascular, Thrombotic, and Valvular Disease. Circulation. 2020;141:1826–1828. doi: 10.1161/CIRCULATIONAHA.120.045826 LarssonSC GillD MasonAM Lipoprotein(a) in Alzheimer, Atherosclerotic, Cerebrovascular, Thrombotic, and Valvular Disease Circulation 2020 141 1826 1828 10.1161/CIRCULATIONAHA.120.045826 Open DOISearch in Google Scholar

28. Anagnostis P, Antza C, Trakatelli C, et al. The effect of menopause on lipoprotein(a) concentrations: a systematic review and meta-analysis. Maturitas. 2023;167:39–45. doi: 10.1016/j.maturitas.2022.09.012 AnagnostisP AntzaC TrakatelliC The effect of menopause on lipoprotein(a) concentrations: a systematic review and meta-analysis Maturitas 2023 167 39 45 10.1016/j.maturitas.2022.09.012 Open DOISearch in Google Scholar

29. Anagnostis P, Galanis P, Chatzistergiou V, et al. The effect of hormone replacement therapy and tibolone on lipoprotein (a) concentrations in postmenopausal women: a systematic review and meta-analysis. Maturitas. 2017;27–36. doi: 10.1016/j.maturitas.2017.02.009 AnagnostisP GalanisP ChatzistergiouV The effect of hormone replacement therapy and tibolone on lipoprotein (a) concentrations in postmenopausal women: a systematic review and meta-analysis Maturitas 2017 27 36 10.1016/j.maturitas.2017.02.009 Open DOISearch in Google Scholar

30. Stiekema LCA, Prange KHM, Hoogeveen RM, et al. Potent lipoprotein(a) lowering following apolipoprotein(a) antisense treatment reduces the pro-inflammatory activation of circulating monocytes in patients with elevated lipoprotein(a). Eur Heart J. 2020;41:2262–2271. doi: 10.1093/eurheartj/ehaa171 StiekemaLCA PrangeKHM HoogeveenRM Potent lipoprotein(a) lowering following apolipoprotein(a) antisense treatment reduces the pro-inflammatory activation of circulating monocytes in patients with elevated lipoprotein(a) Eur Heart J 2020 41 2262 2271 10.1093/eurheartj/ehaa171 Open DOISearch in Google Scholar

31. O'Donoghue ML, López JAG, Knusel B, et al. Study design and rationale for the Olpasiran trials of Cardiovascular Events And lipoprotein(a) reduction-DOSE finding study (OCEAN(a)-DOSE). Am Heart J. 2022;251:61–69. doi: 10.1016/j.ahj.2022.05.004 O'DonoghueML LópezJAG KnuselB Study design and rationale for the Olpasiran trials of Cardiovascular Events And lipoprotein(a) reduction-DOSE finding study (OCEAN(a)-DOSE) Am Heart J 2022 251 61 69 10.1016/j.ahj.2022.05.004 Open DOISearch in Google Scholar

32. Waldmann E, Parhofer KG. Apheresis for severe hypercholesterolaemia and elevated lipoprotein(a). Pathology. 2019;51:227–232. doi: 10.1016/j.pathol.2018.10.016 WaldmannE ParhoferKG Apheresis for severe hypercholesterolaemia and elevated lipoprotein(a) Pathology 2019 51 227 232 10.1016/j.pathol.2018.10.016 Open DOISearch in Google Scholar

33. Sachais BS, Shaz BH. Apheresis to mitigate atherosclerotic vascular disease. Am J Hypertens. 2018;31:945–949. doi: 10.1093/ajh/hpy068 SachaisBS ShazBH Apheresis to mitigate atherosclerotic vascular disease Am J Hypertens 2018 31 945 949 10.1093/ajh/hpy068 Open DOISearch in Google Scholar

34. Pokrovsky SN, Afanasieva OI, Ezhov MV. Therapeutic apheresis for management of Lp(a) hyperlipoproteinemia. Curr Atheroscler Rep. 2020;22:68. doi: 10.1007/s11883-020-00886-0 PokrovskySN AfanasievaOI EzhovMV Therapeutic apheresis for management of Lp(a) hyperlipoproteinemia Curr Atheroscler Rep 2020 22 68 10.1007/s11883-020-00886-0 Open DOISearch in Google Scholar

35. O'Donoghue ML, Fazio S, Giugliano RP, et al. Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk insights from the FOURIER trial. Circulation. 2019;139:1483–1492. doi: 10.1161/CIRCULATIONAHA.118.037184 O'DonoghueML FazioS GiuglianoRP Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk insights from the FOURIER trial Circulation 2019 139 1483 1492 10.1161/CIRCULATIONAHA.118.037184 Open DOISearch in Google Scholar

36. Bittner VA, Szarek M, Aylward PE, et al. Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome. J Am Coll Cardiol. 2020;75:133–144. doi: 10.1016/j.jacc.2019.10.057 BittnerVA SzarekM AylwardPE Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome J Am Coll Cardiol 2020 75 133 144 10.1016/j.jacc.2019.10.057 Open DOISearch in Google Scholar

37. Raal FJ, Kallend D, Ray KK, et al. Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia. N Engl J Med. 2020;382:1520–1530. doi: 10.1056/NEJMoa1913805 RaalFJ KallendD RayKK Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia N Engl J Med 2020 382 1520 1530 10.1056/NEJMoa1913805 Open DOISearch in Google Scholar

38. Koutsogianni A, Liamis G, Liberopoulos E, et al. Effects of Lipid-Modifying and Other Drugs on Lipoprotein(a) Levels—Potent Clinical Implications. Pharmaceuticals. 2023;16:750. doi: 10.3390/ph16050750 KoutsogianniA LiamisG LiberopoulosE Effects of Lipid-Modifying and Other Drugs on Lipoprotein(a) Levels—Potent Clinical Implications Pharmaceuticals 2023 16 750 10.3390/ph16050750 Open DOISearch in Google Scholar

39. Kronenberg F, Mora S, Stroes E, et.al. From the EAS: frequent questions and responses on the 2022 lipoprotein(a) consensus statement of the European Atherosclerosis Society. Atherosclerosis. 2023;374(Suppl 1). doi: 10.1016/j.atherosclerosis.2023.04.012 KronenbergF MoraS StroesE From the EAS: frequent questions and responses on the 2022 lipoprotein(a) consensus statement of the European Atherosclerosis Society Atherosclerosis 2023 374 Suppl 1 10.1016/j.atherosclerosis.2023.04.012 Open DOISearch in Google Scholar

40. Masson W, Waisman G, Corral P, et.al. Impact of Lipoprotein(a) Levels on Cardiovascular Risk Estimation. High Blood Press Cardiovasc Prev. 2024. doi: 10.1007/s40292-024-00649-x MassonW WaismanG CorralP Impact of Lipoprotein(a) Levels on Cardiovascular Risk Estimation High Blood Press Cardiovasc Prev. 2024 10.1007/s40292-024-00649-x Open DOISearch in Google Scholar

41. Hadi A, Askarpour M, Ziaei R, et al. Impact of flaxseed supplementation on plasma lipoprotein(a) concentrations: A systematic review and meta-analysis of randomized controlled trials. Phytother Res. 2020;34:1599–1608. doi: 10.1002/ptr.6640 HadiA AskarpourM ZiaeiR Impact of flaxseed supplementation on plasma lipoprotein(a) concentrations: A systematic review and meta-analysis of randomized controlled trials Phytother Res 2020 34 1599 1608 10.1002/ptr.6640 Open DOISearch in Google Scholar